candesartan has been researched along with Disease Exacerbation in 34 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The addition of candesartan to ACE inhibitor and beta-blocker decreases Nt-proBNP and hsCRP, but does not change the other markers of inflammation or oxidative stress in patients with heart failure." | 9.12 | Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. ( Dabouz, F; De Denus, S; Ducharme, A; Gossard, D; Lavoie, J; Leblanc, MH; Lepage, S; Racine, N; Rouleau, JL; Touyz, R; White, M; Whittom, L, 2007) |
| "Candesartan reduced sudden death and death from worsening heart failure in patients with symptomatic heart failure, although this reduction was most apparent in patients with systolic dysfunction." | 9.11 | Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. ( Finn, P; Granger, CB; McMurray, JJ; Michelson, EL; Pfeffer, MA; Pocock, S; Skali, H; Solomon, SD; Swedberg, K; Wang, D; Yusuf, S; Zornoff, L, 2004) |
| "The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme consists of three randomised, double-masked, parallel, placebo-controlled studies to determine the impact of treatment with candesartan on diabetic retinopathy." | 9.10 | The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. ( Chaturvedi, N; Sjoelie, AK; Svensson, A, 2002) |
| "The present study demonstrates that in animals with a non-ACE pathway, candesartan suppressed myocardial fibrosis during the progression of CHF in comparison with enalapril." | 7.72 | Candesartan prevents myocardial fibrosis during progression of congestive heart failure. ( Dohi, K; Funabiki, K; Imanaka-Yoshida, K; Ito, M; Kitamura, T; Koji, T; Nakano, T; Nobori, T; Onishi, K, 2004) |
| "Given the association of diabetic retinopathy (DR) and kidney disease, we investigated the urinary peptidome to presence and deterioration of DR in a post hoc analysis of trials investigating the effect of candesartan on progression of DR in type 1 and type 2 diabetes, respectively." | 5.41 | Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials. ( Hansen, TW; He, T; Magalhães, P; Mischak, H; Rossing, P; Rotbain Curovic, V, 2021) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of candesartan in acute stroke." | 5.16 | Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. ( Bath, PM; Berge, E; Kjeldsen, SE; Murray, GD; Sandset, EC, 2012) |
| "To study the association between baseline retinal microaneurysm score and progression and regression of diabetic retinopathy, and response to treatment with candesartan in people with diabetes." | 5.15 | Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme. ( Aldington, S; Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "The addition of candesartan to ACE inhibitor and beta-blocker decreases Nt-proBNP and hsCRP, but does not change the other markers of inflammation or oxidative stress in patients with heart failure." | 5.12 | Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. ( Dabouz, F; De Denus, S; Ducharme, A; Gossard, D; Lavoie, J; Leblanc, MH; Lepage, S; Racine, N; Rouleau, JL; Touyz, R; White, M; Whittom, L, 2007) |
| "Candesartan reduced sudden death and death from worsening heart failure in patients with symptomatic heart failure, although this reduction was most apparent in patients with systolic dysfunction." | 5.11 | Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. ( Finn, P; Granger, CB; McMurray, JJ; Michelson, EL; Pfeffer, MA; Pocock, S; Skali, H; Solomon, SD; Swedberg, K; Wang, D; Yusuf, S; Zornoff, L, 2004) |
| "The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme consists of three randomised, double-masked, parallel, placebo-controlled studies to determine the impact of treatment with candesartan on diabetic retinopathy." | 5.10 | The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. ( Chaturvedi, N; Sjoelie, AK; Svensson, A, 2002) |
| " Therefore, in the current study we examined the effects of Candesartan and Compound 21 (C21) (RAS modulators) on aspects of cognition known to diminish with advanced age and accelerate with hypertension and vascular disease." | 3.88 | Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study. ( Ahmed, HA; Arbab, AS; Bunting, KM; Ergul, A; Fagan, SC; Ishrat, T; Patel, A; Pillai, B; Vazdarjanova, A; Waller, JL, 2018) |
| "We performed a post hoc analysis in the Diabetic Retinopathy Candesartan Trials (DIRECT-Protect 2 study), a multi centric randomized clinical controlled trial." | 3.85 | Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. ( Bilous, R; Chaturvedi, N; de Zeeuw, D; Fuller, J; Klein, R; Lambers Heerspink, H; Lindhardt, M; Mischak, H; Orchard, T; Parving, HH; Persson, F; Porta, M; Rossing, P; Stalmach, A; Zürbig, P, 2017) |
| "Prevention is an important goal in the treatment of hypertension." | 3.79 | Prehypertension: a possible target for antihypertensive medication. ( Julius, S; Nesbitt, SD, 2000) |
| " The effects of AT1 receptor blocker candesartan were evaluated in a mouse model of peritoneal carcinomatosis." | 3.75 | Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. ( Fujimura, T; Fujita, H; Fushida, S; Harada, S; Hirakawa, K; Kayahara, M; Kinami, S; Kinoshita, J; Ninomiya, I; Ohta, T; Yagi, Y; Yashiro, M, 2009) |
| "All 2,679 symptomatic chronic heart failure patients from the North American CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program had a wide range of laboratory measures performed at a core facility, enabling us to assess the relationship between routine blood tests and outcomes using a Cox proportional hazards model." | 3.74 | Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. ( Allen, LA; Felker, GM; Granger, CB; McMurray, JJ; Michelson, EL; Pfeffer, MA; Pocock, SJ; Shaw, LK; Swedberg, K; Wang, D; Yusuf, S, 2007) |
| "The present study demonstrates that in animals with a non-ACE pathway, candesartan suppressed myocardial fibrosis during the progression of CHF in comparison with enalapril." | 3.72 | Candesartan prevents myocardial fibrosis during progression of congestive heart failure. ( Dohi, K; Funabiki, K; Imanaka-Yoshida, K; Ito, M; Kitamura, T; Koji, T; Nakano, T; Nobori, T; Onishi, K, 2004) |
| "Standard ACEI plus candesartan is more effective in reducing systolic blood pressure and proteinuria than a 50% increase in ACEI dose." | 3.72 | Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. ( Fairley, KF; Kincaid-Smith, P; Packham, D, 2004) |
| "Hypertension has long been recognized as a major risk factor of several cardiovascular diseases." | 2.44 | [Role of RAS in prehypertension]. ( Horiuchi, M; Inaba, S; Iwai, M, 2008) |
| "Prehypertension is a recognized stage of blood pressure but treatment standards have not yet been established." | 2.44 | Treatment options for prehypertension. ( Nesbitt, SD, 2007) |
| "Candesartan treatment alleviated matrisome protein accumulation and normalized the vascular distensibility and cerebral blood flow." | 1.62 | Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model. ( Ando, S; Fujita, N; Fukunaga, M; Hasegawa, M; Hatano, Y; Hirokawa, S; Igarashi, H; Ihara, M; Kakita, A; Kametani, F; Kanazawa, M; Kato, T; Kawashima, Y; Kawata, H; Koyama, A; Manabe, RI; Matsumoto, M; Murayama, S; Nishizawa, M; Nozaki, H; Onodera, O; Saito, R; Saito, S; Sato, T; Sekine, Y; Sugai, A; Sugie, A; Toyoshima, Y; Tsuji, S; Uemura, M, 2021) |
| "Gross proteinuria was largely unaffected by (AT1R) blockade and renal function further declined necessitating, initiation of hemodialysis." | 1.36 | Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization. ( Biesenbach, P; Gremmel, T; Hörl, WH; Kain, R; Säemann, MD, 2010) |
| "A 31-year-old woman developed bilateral posterior ischemic optic neuropathy and infarctions of the cerebral arterial border zones and spinal cord after correction of malignant hypertension." | 1.35 | Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension. ( An, SJ; Choi, JH; Choi, KD; Kim, HJ; Kim, JS; Lee, JE, 2008) |
| "Angiotensin (Ang) II-induced abdominal aortic aneurysm (AAA) in apoE-deficient mice has been used as a model of human AAA, but it has been unclear why the progression of AAA continues after stopping the Ang II infusion." | 1.35 | Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient mice. ( Hayashi, T; Inoue, N; Jin, D; Katayama, H; Kitaura, Y; Miyazaki, M; Muramatsu, M; Takai, S; Tamai, H, 2009) |
| "Atherosclerotic renal artery stenosis is a problem with no consensus on diagnosis or therapy." | 1.33 | Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. ( Cohen, DJ; Cooper, CJ; D'Agostino, R; Dworkin, L; Henrich, W; Jaff, M; Jamerson, K; Kuntz, R; Matsumoto, A; Murphy, TP; Reid, D; Rosenfield, K; Rundback, J; Steffes, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (64.71) | 29.6817 |
| 2010's | 10 (29.41) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, T | 1 |
| Manabe, RI | 1 |
| Igarashi, H | 1 |
| Kametani, F | 1 |
| Hirokawa, S | 1 |
| Sekine, Y | 1 |
| Fujita, N | 1 |
| Saito, S | 1 |
| Kawashima, Y | 1 |
| Hatano, Y | 1 |
| Ando, S | 1 |
| Nozaki, H | 1 |
| Sugai, A | 1 |
| Uemura, M | 1 |
| Fukunaga, M | 1 |
| Sato, T | 1 |
| Koyama, A | 1 |
| Saito, R | 1 |
| Sugie, A | 1 |
| Toyoshima, Y | 1 |
| Kawata, H | 1 |
| Murayama, S | 1 |
| Matsumoto, M | 1 |
| Kakita, A | 1 |
| Hasegawa, M | 1 |
| Ihara, M | 1 |
| Kanazawa, M | 1 |
| Nishizawa, M | 1 |
| Tsuji, S | 1 |
| Onodera, O | 1 |
| Rotbain Curovic, V | 1 |
| Magalhães, P | 1 |
| He, T | 1 |
| Hansen, TW | 1 |
| Mischak, H | 2 |
| Rossing, P | 2 |
| Ahmed, HA | 1 |
| Ishrat, T | 1 |
| Pillai, B | 1 |
| Bunting, KM | 1 |
| Patel, A | 1 |
| Vazdarjanova, A | 1 |
| Waller, JL | 1 |
| Arbab, AS | 1 |
| Ergul, A | 1 |
| Fagan, SC | 1 |
| Helske-Suihko, S | 1 |
| Laine, M | 1 |
| Lommi, J | 1 |
| Kaartinen, M | 1 |
| Werkkala, K | 1 |
| Kovanen, PT | 1 |
| Kupari, M | 1 |
| Damman, K | 1 |
| Solomon, SD | 3 |
| Pfeffer, MA | 4 |
| Swedberg, K | 4 |
| Yusuf, S | 4 |
| Young, JB | 2 |
| Rouleau, JL | 2 |
| Granger, CB | 4 |
| McMurray, JJ | 4 |
| Lindhardt, M | 1 |
| Persson, F | 1 |
| Zürbig, P | 1 |
| Stalmach, A | 1 |
| de Zeeuw, D | 1 |
| Lambers Heerspink, H | 1 |
| Klein, R | 2 |
| Orchard, T | 2 |
| Porta, M | 2 |
| Fuller, J | 2 |
| Bilous, R | 2 |
| Chaturvedi, N | 3 |
| Parving, HH | 2 |
| Inaba, S | 1 |
| Iwai, M | 1 |
| Horiuchi, M | 1 |
| Choi, JH | 1 |
| Choi, KD | 1 |
| Kim, JS | 1 |
| Kim, HJ | 1 |
| Lee, JE | 1 |
| An, SJ | 1 |
| Kinoshita, J | 1 |
| Fushida, S | 1 |
| Harada, S | 1 |
| Yagi, Y | 1 |
| Fujita, H | 1 |
| Kinami, S | 1 |
| Ninomiya, I | 1 |
| Fujimura, T | 1 |
| Kayahara, M | 1 |
| Yashiro, M | 1 |
| Hirakawa, K | 1 |
| Ohta, T | 1 |
| Inoue, N | 1 |
| Muramatsu, M | 1 |
| Jin, D | 1 |
| Takai, S | 1 |
| Hayashi, T | 1 |
| Katayama, H | 1 |
| Kitaura, Y | 1 |
| Tamai, H | 1 |
| Miyazaki, M | 1 |
| Frimodt-Møller, M | 1 |
| Høj Nielsen, A | 1 |
| Strandgaard, S | 1 |
| Kamper, AL | 1 |
| Biesenbach, P | 1 |
| Gremmel, T | 1 |
| Hörl, WH | 1 |
| Kain, R | 1 |
| Säemann, MD | 1 |
| Sjølie, AK | 1 |
| Aldington, S | 1 |
| Suzuki, T | 1 |
| Nozawa, T | 1 |
| Fujii, N | 1 |
| Sobajima, M | 1 |
| Ohori, T | 1 |
| Shida, T | 1 |
| Matsuki, A | 1 |
| Kameyama, T | 1 |
| Inoue, H | 1 |
| Yasuda, N | 1 |
| Akazawa, H | 1 |
| Ito, K | 1 |
| Shimizu, I | 1 |
| Kudo-Sakamoto, Y | 1 |
| Yabumoto, C | 1 |
| Yano, M | 1 |
| Yamamoto, R | 1 |
| Ozasa, Y | 1 |
| Minamino, T | 1 |
| Naito, AT | 1 |
| Oka, T | 1 |
| Shiojima, I | 1 |
| Tamura, K | 1 |
| Umemura, S | 1 |
| Paradis, P | 1 |
| Nemer, M | 1 |
| Komuro, I | 1 |
| Sandset, EC | 1 |
| Murray, GD | 1 |
| Bath, PM | 1 |
| Kjeldsen, SE | 2 |
| Berge, E | 1 |
| Sjoelie, AK | 1 |
| Svensson, A | 1 |
| Onishi, K | 1 |
| Dohi, K | 1 |
| Koji, T | 1 |
| Funabiki, K | 1 |
| Kitamura, T | 1 |
| Imanaka-Yoshida, K | 1 |
| Ito, M | 1 |
| Nobori, T | 1 |
| Nakano, T | 1 |
| Kincaid-Smith, P | 1 |
| Fairley, KF | 1 |
| Packham, D | 1 |
| Wang, D | 2 |
| Finn, P | 1 |
| Skali, H | 2 |
| Zornoff, L | 1 |
| Michelson, EL | 3 |
| Pocock, S | 2 |
| Angioi-Duprez, K | 1 |
| Cooper, CJ | 1 |
| Murphy, TP | 1 |
| Matsumoto, A | 1 |
| Steffes, M | 1 |
| Cohen, DJ | 1 |
| Jaff, M | 1 |
| Kuntz, R | 1 |
| Jamerson, K | 1 |
| Reid, D | 1 |
| Rosenfield, K | 1 |
| Rundback, J | 1 |
| D'Agostino, R | 1 |
| Henrich, W | 1 |
| Dworkin, L | 1 |
| Narkiewicz, K | 1 |
| Hedner, T | 1 |
| Maitland, K | 1 |
| Bridges, L | 1 |
| Davis, WP | 1 |
| Loscalzo, J | 1 |
| Pointer, MA | 1 |
| Kaplan, NM | 1 |
| Bakris, G | 1 |
| Weir, MR | 1 |
| White, M | 1 |
| Lepage, S | 1 |
| Lavoie, J | 1 |
| De Denus, S | 1 |
| Leblanc, MH | 1 |
| Gossard, D | 1 |
| Whittom, L | 1 |
| Racine, N | 1 |
| Ducharme, A | 1 |
| Dabouz, F | 1 |
| Touyz, R | 1 |
| Nesbitt, SD | 2 |
| Felker, GM | 1 |
| Allen, LA | 1 |
| Pocock, SJ | 1 |
| Shaw, LK | 1 |
| Dobson, J | 1 |
| Krämer, S | 1 |
| Kron, S | 1 |
| Wang-Rosenke, Y | 1 |
| Loof, T | 1 |
| Khadzhynov, D | 1 |
| Morgera, S | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Martini, S | 1 |
| Neumayer, HH | 1 |
| Peters, H | 1 |
| Perrin, NE | 1 |
| Jaremko, GA | 1 |
| Berg, UB | 1 |
| Julius, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Potential of Candesartan to Retard the Progression of Aortic Stenosis Influences of Medical Therapy to the Atheroinflammatory Process in Stenotic Aortic Valves[NCT00699452] | Phase 3 | 120 participants (Anticipated) | Interventional | 2009-05-31 | Recruiting | ||
| Prospective, Single-center, Six-month Study of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy: Effects on Microaneurysm Turnover and Non-perfused Retinal Area[NCT02834663] | Phase 4 | 25 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733] | Phase 3 | 5,238 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694] | Phase 3 | 4,717 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720] | Phase 3 | 1,850 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Scandinavian Candesartan Acute Stroke Trial[NCT00120003] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.[NCT01052272] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[NCT00081731] | Phase 3 | 947 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Prognostic Value of Red Cell Distribution Width (RDW) in Neonatal Sepsis in Patients Admitted at Assiut University Children Hospital.[NCT03403062] | 100 participants (Anticipated) | Observational | 2019-02-28 | Not yet recruiting | |||
| Gender Specific Registry in Subjects Hospitalized With Heart Failure in Santiago( GENESIS Registry): Pilot Heart Failure Registry Looking for Sex Analysis[NCT05960968] | 500 participants (Anticipated) | Observational [Patient Registry] | 2023-08-11 | Recruiting | |||
| A Randomized Study of Pocket Ultrasound Derived IVC Diameter for Guided Management of Heart Failure[NCT01962688] | 37 participants (Actual) | Interventional | 2013-08-31 | Terminated (stopped due to low enrollment) | |||
| A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation[NCT01772108] | 42 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to As recruitment rate was lower than anticipated) | |||
| Studies of Early Diabetic Glomerulopathy-the Relation Between Histopathology, Kidney Function and Metabolic Control. Natural History and Effect of ARB[NCT00328302] | Phase 4 | 13 participants | Interventional | 2000-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CRT was performed using OCT at each visit. The OCT measured at each visit was analyzed statistically. the CMT compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | um (Mean) |
|---|---|
| CRT Baseline | 479.12 |
| CRT Resulte | 369.12 |
Using ImageJ software (version 1.52a) by FAG image. The Perifoveal non-perfusion area in FAG compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | mm2 (Mean) |
|---|---|
| Perifoveal Non-perfusion Area Baseline | 2.517 |
| Perifoveal Non-perfusion Area Results | 2.495 |
Systemic adverse events (MI, CVA, etc), Ocular adverse events (retinal detachment, RPE tear, endophthalmitis, uveitis, vitreous hemorrhage, subretinal hemorrhage, cataract , IOP elevation, etc) at baseline and each visit. (NCT02834663)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Safety Parameters Results | 0 |
BCVA was performed using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at baseline and 6 months. The BCVA compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | letters (Mean) |
|---|---|
| BCVA Baseline | 67.6 |
| BCVA Resulte | 76.36 |
Number of MAs that resolved/month The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm disappearance rate compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms/month (Mean) |
|---|---|
| The MA Disappearance Rate Baseline | 4.40 |
| The MA Disappearance Rate Resulte | 0.96 |
number of new MAs detected/month The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm formation rate compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms/month (Mean) |
|---|---|
| The MA Formation Rate Baseline | 2.48 |
| The MA Formation Rate Resulte | 0.96 |
The microaneurysm formation rate + The microaneurysm disappearance rate The MAs in individual retinas were evaluated at 6 months using fundus photography. The Retmarker (version 1.0.2 by Retmarker Ltd, Coimbra, Portugal) software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. MA turnover was calculated by adding the MA formation rate (number of new MAs detected/month) to the MA disappearance rate (number of MAs that resolved/month). The microaneurysm turnover compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms/month (Mean) |
|---|---|
| The Microaneurysm Turnover Baseline | 6.88 |
| The Microaneurysm Turnover Results | 1.92 |
The number of MAs in individual retinas were evaluated during 6 months using fundus photography and FA imaging. The Retmarker software was used for automatic measurement and analysis of changes in number and extent of MAs on fundus photographs and to calculate the total number and turnover of MAs. Changes in MAs were analyzed statistically. the total number of MAs compare the degree of improvement or worsening of vision at baseline and 6 months. (value at 6 months minus value at baseline) (NCT02834663)
Timeframe: 6 months
| Intervention | microaneurysms (Mean) |
|---|---|
| Total MA Baseline | 5.68 |
| Total MA Resulte | 1.60 |
Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 178 |
| Placebo | 217 |
An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.510 |
| Placebo | 0.543 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 161 |
| Placebo | 182 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 180 |
| Placebo | 136 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 192 |
| Placebo | 193 |
An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/1000 year (Least Squares Mean) |
|---|---|
| Candesartan | 656 |
| Placebo | 718 |
Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 127 |
| Placebo | 124 |
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 140 |
| Placebo | 139 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 110 |
| Placebo | 107 |
An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.569 |
| Placebo | 0.642 |
LVEF is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 56.36 | 56.82 | 42.62 | 52.37 | 39.88 | 56.33 | NA | 51.70 | 54.17 |
| Candesartan Cilexetil and Allopurinol | 52.68 | 57.28 | NA | 56.11 | 54.46 | 57.82 | 56.17 | 55.79 | 54.40 |
| Ramipril | 52.19 | 54.20 | 64.98 | 52.76 | 52.13 | 55.02 | 51.27 | 57.18 | 50.73 |
| Ramipril and Allopurinol | 53.37 | 52.80 | NA | 51.74 | 34.89 | 54.05 | NA | 55.59 | NA |
LVEDV/BSA: As an indicator of heart size, the blood volume of the heart is related to the body size. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 78.06 | 78.60 | 93.57 | 85.44 | 90.20 | 82.74 | NA | 84.28 | 76.65 |
| Candesartan Cilexetil and Allopurinol | 79.03 | 78.01 | NA | 79.75 | 63.1 | 84.95 | 75.27 | 79.72 | 75.05 |
| Ramipril | 73.03 | 74.10 | 73.23 | 75.34 | 81.19 | 75.28 | 71.99 | 70.46 | 48.68 |
| Ramipril and Allopurinol | 78.52 | 86.13 | NA | 83.95 | 108.25 | 67.96 | NA | 71.63 | NA |
LVESV/BSA: The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 35.26 | 35.26 | 53.87 | 42.27 | 54.04 | 37.76 | NA | 41.72 | 35.13 |
| Candesartan Cilexetil and Allopurinol | 39.49 | 34.15 | NA | 36.07 | 28.74 | 37.18 | 32.99 | 35.99 | 34.22 |
| Ramipril | 36.20 | 34.77 | 25.64 | 36.82 | 39.42 | 35.30 | 35.23 | 31.17 | 23.98 |
| Ramipril and Allopurinol | 37.91 | 42.88 | NA | 42.34 | 70.48 | 30.39 | NA | 31.56 | NA |
LVED Mass/LVEDV: As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 0.95 | 0.83 | 0.67 | 0.78 | 0.70 | 0.79 | NA | 0.80 | 0.64 |
| Candesartan Cilexetil and Allopurinol | 0.87 | 0.82 | NA | 0.86 | 0.68 | 0.80 | 0.69 | 0.82 | 0.69 |
| Ramipril | 0.92 | 0.87 | 0.75 | 0.84 | 0.81 | 0.79 | 0.95 | 0.84 | 0.93 |
| Ramipril and Allopurinol | 0.86 | 0.71 | NA | 0.72 | 0.57 | 0.83 | NA | 0.80 | NA |
LVED Radius/Wall thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 3.14 | 3.39 | 4.14 | 3.68 | 4.10 | 3.71 | NA | 3.58 | 4.04 |
| Candesartan Cilexetil and Allopurinol | 3.45 | 3.63 | NA | 3.42 | 3.90 | 3.56 | 4.24 | 3.56 | 4.29 |
| Ramipril | 3.23 | 3.32 | 3.42 | 3.43 | 3.44 | 3.60 | 2.92 | 3.46 | 3.12 |
| Ramipril and Allopurinol | 3.57 | 4.04 | NA | 4.01 | 4.57 | 3.60 | NA | 3.61 | NA |
By identifying three points in three different planes in the heart muscle, the maximum shortening is the average of the difference between the distance between these three points at the end of filling of the heart and the end of contraction divided by the length at the end of filling times 100. The maximum shortening is a three dimensional analysis. The higher values indicate a healthy heart. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent of length at end of filling (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,17,18) | Month 6(n=14,11,10,12) | Month 9(n=1,2,0,0) | Month 12(n=11,11,10,10) | Month 15(n=3,2,1,1) | Month 18(n=10,12,7,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 16.68 | 17.50 | 19.08 | 17.13 | 16.28 | 17.55 | NA | 16.62 | 20.38 |
| Candesartan Cilexetil and Allopurinol | 16.00 | 18.50 | NA | 18.51 | 16.36 | 17.52 | 17.89 | 17.85 | 16.59 |
| Ramipril | 15.81 | 16.88 | 18.43 | 14.57 | 17.06 | 17.26 | 16.68 | 15.67 | 13.70 |
| Ramipril and Allopurinol | 15.84 | 18.72 | NA | 17.96 | 14.22 | 17.46 | NA | 17.52 | NA |
The Peak Early Filling Rate Normalized to EDV is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | 1/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 2.01 | 2.02 | 1.13 | 1.90 | 1.48 | 1.93 | NA | 1.65 | 1.10 |
| Candesartan Cilexetil and Allopurinol | 2.0 | 1.98 | NA | 1.77 | 2.28 | 2.05 | 2.50 | 1.82 | 2.15 |
| Ramipril | 1.93 | 1.74 | 2.50 | 1.80 | 2.02 | 1.91 | 1.69 | 2.05 | 1.34 |
| Ramipril and Allopurinol | 2.11 | 2.03 | NA | 1.93 | 1.56 | 1.89 | NA | 1.88 | NA |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 77 |
| Stenting | 68 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 20 |
| Stenting | 20 |
Only the first event per participant is included in the composite (NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 169 |
| Stenting | 161 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 26 |
| Stenting | 27 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 27 |
| Stenting | 30 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 3 |
| Stenting | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 16 |
| Stenting | 12 |
hospitalization information will be recorded throughout the length of the study for the outpatient arms (NCT01962688)
Timeframe: up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Handheld Ultrasound | 4 |
| Clinical Assessment Only | 5 |
hospitalization information will be recorded throughout the length of the study for the inpatient arms (NCT01962688)
Timeframe: up to 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Handheld Ultrasound | 6 |
| Clinical Assessment Only | 18 |
"New York Heart Association (NYHA) Classification Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.~Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.~Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100m). Comfortable only at rest.~Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients." (NCT01962688)
Timeframe: 6 months
| Intervention | visits (Number) | |||
|---|---|---|---|---|
| NYHA Class I | NYHA Class II | NYHA Class III | NYHA Class IV | |
| Clinical Assessment Only | 1 | 18 | 39 | 2 |
| Handheld Ultrasound | 0 | 9 | 22 | 0 |
4 reviews available for candesartan and Disease Exacerbation
| Article | Year |
|---|---|
[Role of RAS in prehypertension].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular | 2008 |
[Retinopathy, a major cause of blindness in the adult diabetic].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blindness; Causality; D | 2006 |
Treatment options for prehypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2007 |
Prehypertension: a possible target for antihypertensive medication.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2000 |
10 trials available for candesartan and Disease Exacerbation
| Article | Year |
|---|---|
Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compounds; Cros | 2021 |
Is blockade of the Renin-Angiotensin system able to reverse the structural and functional remodeling of the left ventricle in severe aortic stenosis?
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Aortic Valve Stenosis; Benzimidazo | 2015 |
Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2010 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.
Topics: Adult; Aneurysm; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabet | 2011 |
Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2012 |
The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Retinopathy; Disease Progressi | 2002 |
Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Canada; Cardiovas | 2004 |
Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biopsy; Biphenyl Compounds; Blood Pr | 2008 |
Prehypertension: a possible target for antihypertensive medication.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2000 |
21 other studies available for candesartan and Disease Exacerbation
| Article | Year |
|---|---|
Candesartan prevents arteriopathy progression in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy model.
Topics: ADAMTS Proteins; Alopecia; Animals; Benzimidazoles; Biphenyl Compounds; Cerebral Infarction; Cerebro | 2021 |
Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2018 |
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Creatinine; Disease Prog | 2016 |
Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Com | 2017 |
Simultaneous posterior ischemic optic neuropathy, cerebral border zone infarction, and spinal cord infarction after correction of malignant hypertension.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Brain; Brain Stem Infarctions; C | 2008 |
Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Angiotensin II; A | 2009 |
Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2009 |
Gross proteinuria and subacute renal failure after coronary angiography - a case report of cholesterol crystal embolization.
Topics: Acute Kidney Injury; Angiotensin II Type 1 Receptor Blockers; Austria; Benzimidazoles; Biopsy; Biphe | 2010 |
Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Atherosclerosis; Atorvastat | 2011 |
Agonist-independent constitutive activity of angiotensin II receptor promotes cardiac remodeling in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2012 |
Candesartan prevents myocardial fibrosis during progression of congestive heart failure.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Disease Progression; Dogs; Fibrosis; Heart Failure; Mal | 2004 |
Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2004 |
Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial.
Topics: Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Biph | 2006 |
An American TROPHY in the prevention of hypertension.
Topics: Benzimidazoles; Biphenyl Compounds; Disease Progression; Female; Humans; Hypertension; Male; Middle | 2006 |
Different effects of angiotensin receptor blockade on end-organ damage in salt-dependent and salt-independent hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
TROPHY: a trial that may change clinical practice.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2006 |
The continuum of blood pressure risk: when is the best time to intervene?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2006 |
Treatment of prehypertension: how soon is soon enough? What therapy should be used?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2006 |
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank.
Topics: Aged; Benzimidazoles; Biomarkers; Biphenyl Compounds; Cause of Death; Cohort Studies; Databases as T | 2007 |
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Topics: Aftercare; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Bipheny | 2007 |
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Topics: Aftercare; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Bipheny | 2007 |
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Topics: Aftercare; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Bipheny | 2007 |
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Topics: Aftercare; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Bipheny | 2007 |
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Topics: Aftercare; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Bipheny | 2007 |
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Topics: Aftercare; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Bipheny | 2007 |
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Topics: Aftercare; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Bipheny | 2007 |
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Topics: Aftercare; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Bipheny | 2007 |
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure.
Topics: Aftercare; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Bipheny | 2007 |
Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Disease Models, Animal; Disease Progression; Drug Thera | 2008 |